Page last updated: 2024-11-05

ici 204,219 and Dyspnea

ici 204,219 has been researched along with Dyspnea in 2 studies

zafirlukast: a leukotriene D4 receptor antagonist

Dyspnea: Difficult or labored breathing.

Research Excerpts

ExcerptRelevanceReference
"ICI 204,219 is a potent, selective, orally active LT antagonist currently undergoing clinical trials."1.28The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. ( Aharony, D; Bernstein, PR; Brown, FJ; Buckner, CK; Keith, RA; Krell, RD; Kusner, EJ; Matassa, VG; Snyder, DW; Yee, YK, 1990)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Matassa, VG2
Maduskuie, TP1
Shapiro, HS1
Hesp, B1
Snyder, DW2
Aharony, D2
Krell, RD2
Keith, RA2
Buckner, CK1
Kusner, EJ1
Bernstein, PR1
Yee, YK1
Brown, FJ1

Other Studies

2 other studies available for ici 204,219 and Dyspnea

ArticleYear
Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.
    Journal of medicinal chemistry, 1990, Volume: 33, Issue:6

    Topics: Animals; Dyspnea; Guinea Pigs; In Vitro Techniques; Indazoles; Indoles; Muscle Contraction; Pyrazole

1990
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
    The American review of respiratory disease, 1990, Volume: 141, Issue:4 Pt 1

    Topics: Airway Resistance; Animals; Bronchial Spasm; Capillary Permeability; Chemical Phenomena; Chemistry;

1990